ID   TLR9_HUMAN              Reviewed;        1032 AA.
AC   Q9NR96; B3Y661; D1CS56; Q6UVZ2; Q9HD68; Q9HD69; Q9HD70; Q9NYC2; Q9NYC3;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   31-JAN-2002, sequence version 2.
DT   07-APR-2021, entry version 187.
DE   RecName: Full=Toll-like receptor 9;
DE   AltName: CD_antigen=CD289;
DE   Flags: Precursor;
GN   Name=TLR9; ORFNames=UNQ5798/PRO19605;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Monocytic leukemia;
RX   PubMed=11022119;
RA   Du X., Poltorak A., Wei Y., Beutler B.;
RT   "Three novel mammalian Toll-like receptors: gene structure, expression, and
RT   evolution.";
RL   Eur. Cytokine Netw. 11:362-371(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 3; 4 AND 5).
RC   TISSUE=Placenta;
RX   PubMed=11022120;
RA   Chuang T.-H., Ulevitch R.J.;
RT   "Cloning and characterization of a sub-family of human Toll-like receptors:
RT   hTLR7, hTLR8 and hTLR9.";
RL   Eur. Cytokine Netw. 11:372-378(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11130078; DOI=10.1038/35047123;
RA   Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H.,
RA   Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S.;
RT   "A Toll-like receptor recognizes bacterial DNA.";
RL   Nature 408:740-745(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Liu Z., Wang J., Xiao W.;
RL   Submitted (SEP-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=18810425; DOI=10.1007/s00251-008-0332-0;
RA   Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T., Kimura A.;
RT   "Natural selection in the TLR-related genes in the course of primate
RT   evolution.";
RL   Immunogenetics 60:727-735(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=19924287; DOI=10.1371/journal.pone.0007803;
RA   Georgel P., Macquin C., Bahram S.;
RT   "The heterogeneous allelic repertoire of human Toll-Like receptor (TLR)
RT   genes.";
RL   PLoS ONE 4:E7803-E7803(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=11564765; DOI=10.4049/jimmunol.167.7.3555;
RA   Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., Gursel M.,
RA   Klinman D.M.;
RT   "Role of Toll-like receptor 9 in CpG DNA-induced activation of human
RT   cells.";
RL   J. Immunol. 167:3555-3558(2001).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH BTK.
RX   PubMed=17932028; DOI=10.1074/jbc.m707682200;
RA   Doyle S.L., Jefferies C.A., Feighery C., O'Neill L.A.;
RT   "Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine
RT   kinase.";
RL   J. Biol. Chem. 282:36953-36960(2007).
RN   [12]
RP   INTERACTION WITH CNPY3 AND HSP90B1.
RX   PubMed=20865800; DOI=10.1038/ncomms1070;
RA   Liu B., Yang Y., Qiu Z., Staron M., Hong F., Li Y., Wu S., Li Y., Hao B.,
RA   Bona R., Han D., Li Z.;
RT   "Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a
RT   substrate-specific cochaperone.";
RL   Nat. Commun. 1:79-79(2010).
RN   [13]
RP   ERRATUM OF PUBMED:20865800.
RA   Liu B., Yang Y., Qiu Z., Staron M., Hong F., Li Y., Wu S., Li Y., Hao B.,
RA   Bona R., Han D., Li Z.;
RL   Nat. Commun. 3:653-653(2012).
RN   [14]
RP   FUNCTION.
RX   PubMed=23857366; DOI=10.1002/eji.201243068;
RA   Li F.J., Schreeder D.M., Li R., Wu J., Davis R.S.;
RT   "FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell
RT   differentiation.";
RL   Eur. J. Immunol. 43:2980-2992(2013).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-901 AND MET-933.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Key component of innate and adaptive immunity. TLRs (Toll-
CC       like receptors) control host immune response against pathogens through
CC       recognition of molecular patterns specific to microorganisms. TLR9 is a
CC       nucleotide-sensing TLR which is activated by unmethylated cytidine-
CC       phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6,
CC       leading to NF-kappa-B activation, cytokine secretion and the
CC       inflammatory response (PubMed:11564765, PubMed:17932028). Controls
CC       lymphocyte response to Helicobacter infection (By similarity). Upon CpG
CC       stimulation, induces B-cell proliferation, activation, survival and
CC       antibody production (PubMed:23857366). {ECO:0000250|UniProtKB:Q9EQU3,
CC       ECO:0000269|PubMed:11564765, ECO:0000269|PubMed:17932028,
CC       ECO:0000269|PubMed:23857366}.
CC   -!- SUBUNIT: Monomer and homodimer. Exists as a monomer in the absence of
CC       unmethylated cytidine-phosphate-guanosine (CpG) ligand. Proteolytic
CC       processing of an insertion loop (Z-loop) is required for
CC       homodimerization upon binding to the unmethylated CpG ligand leading to
CC       its activation (By similarity). Interacts with MYD88 via their
CC       respective TIR domains (By similarity). Interacts with BTK
CC       (PubMed:17932028). Interacts (via transmembrane domain) with UNC93B1.
CC       Interacts with CD300LH; the interaction may promote full activation of
CC       TLR9-triggered innate responses (By similarity). Interacts with CNPY3
CC       and HSP90B1; this interaction is required for proper folding in the
CC       endoplasmic reticulum (PubMed:20865800). Interacts with SMPDL3B (By
CC       similarity). {ECO:0000250|UniProtKB:Q2EEY0,
CC       ECO:0000250|UniProtKB:Q9EQU3, ECO:0000269|PubMed:17932028,
CC       ECO:0000269|PubMed:20865800}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:Q9EQU3}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:Q9EQU3}. Endosome
CC       {ECO:0000250|UniProtKB:Q9EQU3}. Lysosome
CC       {ECO:0000250|UniProtKB:Q9EQU3}. Cytoplasmic vesicle, phagosome
CC       {ECO:0000250|UniProtKB:Q9EQU3}. Note=Relocalizes from endoplasmic
CC       reticulum to endosome and lysosome upon stimulation with agonist. Exit
CC       from the ER requires UNC93B1. Endolysosomal localization is required
CC       for proteolytic cleavage and subsequent activation. Intracellular
CC       localization of the active receptor may prevent from responding to self
CC       nucleic acid. {ECO:0000250|UniProtKB:Q9EQU3}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=A;
CC         IsoId=Q9NR96-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=Q9NR96-2; Sequence=VSP_006520;
CC       Name=3;
CC         IsoId=Q9NR96-3; Sequence=VSP_006521;
CC       Name=4;
CC         IsoId=Q9NR96-4; Sequence=VSP_006522;
CC       Name=5;
CC         IsoId=Q9NR96-5; Sequence=VSP_006523;
CC   -!- TISSUE SPECIFICITY: Highly expressed in spleen, lymph node, tonsil and
CC       peripheral blood leukocytes, especially in plasmacytoid pre-dendritic
CC       cells. Levels are much lower in monocytes and CD11c+ immature dendritic
CC       cells. Also detected in lung and liver.
CC   -!- PTM: Activated by proteolytic cleavage of the flexible loop between
CC       repeats LRR14 and LRR15 within the ectodomain. Cleavage requires
CC       UNC93B1. Proteolytically processed by first removing the majority of
CC       the ectodomain by either asparagine endopeptidase (AEP) or a cathepsin
CC       followed by a trimming event that is solely cathepsin mediated and
CC       required for optimal receptor signaling.
CC       {ECO:0000250|UniProtKB:Q9EQU3}.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF259262; AAF72189.1; -; mRNA.
DR   EMBL; AF259263; AAF72190.1; -; mRNA.
DR   EMBL; AF245704; AAF78037.1; -; mRNA.
DR   EMBL; AF246972; AAG01734.1; -; mRNA.
DR   EMBL; AF246973; AAG01735.1; -; mRNA.
DR   EMBL; AF246974; AAG01736.1; -; mRNA.
DR   EMBL; AB045180; BAB19259.1; -; mRNA.
DR   EMBL; EU170540; ABW37075.1; -; Genomic_DNA.
DR   EMBL; EU170541; ABW37076.1; -; Genomic_DNA.
DR   EMBL; EU170542; ABW37077.1; -; Genomic_DNA.
DR   EMBL; EU170543; ABW37078.1; -; Genomic_DNA.
DR   EMBL; AB445673; BAG55070.1; -; mRNA.
DR   EMBL; DQ019992; AAZ95513.1; -; Genomic_DNA.
DR   EMBL; DQ019993; AAZ95514.1; -; Genomic_DNA.
DR   EMBL; DQ019994; AAZ95515.1; -; Genomic_DNA.
DR   EMBL; DQ019995; AAZ95516.1; -; Genomic_DNA.
DR   EMBL; DQ019996; AAZ95517.1; -; Genomic_DNA.
DR   EMBL; DQ019999; AAZ95520.1; -; Genomic_DNA.
DR   EMBL; AY359085; AAQ89443.1; -; mRNA.
DR   EMBL; CH471055; EAW65191.1; -; Genomic_DNA.
DR   EMBL; BC032713; AAH32713.1; -; mRNA.
DR   CCDS; CCDS2848.1; -. [Q9NR96-1]
DR   RefSeq; NP_059138.1; NM_017442.3. [Q9NR96-1]
DR   SMR; Q9NR96; -.
DR   BioGRID; 119902; 48.
DR   DIP; DIP-52371N; -.
DR   IntAct; Q9NR96; 15.
DR   STRING; 9606.ENSP00000417517; -.
DR   BindingDB; Q9NR96; -.
DR   ChEMBL; CHEMBL5804; -.
DR   DrugBank; DB00608; Chloroquine.
DR   DrugBank; DB05530; CPG 10101.
DR   DrugBank; DB05475; Golotimod.
DR   DrugBank; DB01611; Hydroxychloroquine.
DR   DrugBank; DB05463; ISS-1018.
DR   DrugCentral; Q9NR96; -.
DR   GuidetoPHARMACOLOGY; 1759; -.
DR   GlyGen; Q9NR96; 14 sites.
DR   iPTMnet; Q9NR96; -.
DR   PhosphoSitePlus; Q9NR96; -.
DR   BioMuta; TLR9; -.
DR   DMDM; 20140872; -.
DR   jPOST; Q9NR96; -.
DR   MassIVE; Q9NR96; -.
DR   MaxQB; Q9NR96; -.
DR   PaxDb; Q9NR96; -.
DR   PeptideAtlas; Q9NR96; -.
DR   PRIDE; Q9NR96; -.
DR   ProteomicsDB; 82308; -. [Q9NR96-1]
DR   ProteomicsDB; 82309; -. [Q9NR96-2]
DR   ProteomicsDB; 82310; -. [Q9NR96-3]
DR   ProteomicsDB; 82311; -. [Q9NR96-4]
DR   ProteomicsDB; 82312; -. [Q9NR96-5]
DR   Antibodypedia; 34940; 1059 antibodies.
DR   DNASU; 54106; -.
DR   Ensembl; ENST00000360658; ENSP00000353874; ENSG00000239732. [Q9NR96-1]
DR   GeneID; 54106; -.
DR   KEGG; hsa:54106; -.
DR   UCSC; uc003dda.2; human. [Q9NR96-1]
DR   CTD; 54106; -.
DR   DisGeNET; 54106; -.
DR   GeneCards; TLR9; -.
DR   HGNC; HGNC:15633; TLR9.
DR   HPA; ENSG00000239732; Tissue enriched (blood).
DR   MIM; 605474; gene.
DR   neXtProt; NX_Q9NR96; -.
DR   OpenTargets; ENSG00000239732; -.
DR   PharmGKB; PA38010; -.
DR   VEuPathDB; HostDB:ENSG00000239732.3; -.
DR   eggNOG; KOG1747; Eukaryota.
DR   eggNOG; KOG4641; Eukaryota.
DR   GeneTree; ENSGT00940000162493; -.
DR   HOGENOM; CLU_006000_2_0_1; -.
DR   InParanoid; Q9NR96; -.
DR   OMA; LSWDCFG; -.
DR   OrthoDB; 264244at2759; -.
DR   PhylomeDB; Q9NR96; -.
DR   TreeFam; TF325595; -.
DR   PathwayCommons; Q9NR96; -.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1679131; Trafficking and processing of endosomal TLR.
DR   Reactome; R-HSA-168138; Toll Like Receptor 9 (TLR9) Cascade.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975155; MyD88 dependent cascade initiated on endosome.
DR   BioGRID-ORCS; 54106; 5 hits in 983 CRISPR screens.
DR   GeneWiki; TLR9; -.
DR   GenomeRNAi; 54106; -.
DR   Pharos; Q9NR96; Tclin.
DR   PRO; PR:Q9NR96; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9NR96; protein.
DR   Bgee; ENSG00000239732; Expressed in blood and 84 other tissues.
DR   Genevisible; Q9NR96; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0032009; C:early phagosome; ISS:UniProtKB.
DR   GO; GO:0036019; C:endolysosome; ISS:UniProtKB.
DR   GO; GO:0036020; C:endolysosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005764; C:lysosome; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005149; F:interleukin-1 receptor binding; IPI:UniProtKB.
DR   GO; GO:0038187; F:pattern recognition receptor activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0035197; F:siRNA binding; IMP:UniProtKB.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:InterPro.
DR   GO; GO:0045322; F:unmethylated CpG binding; ISS:UniProtKB.
DR   GO; GO:0042742; P:defense response to bacterium; NAS:UniProtKB.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IMP:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IBA:GO_Central.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; TAS:BHF-UCL.
DR   GO; GO:0030277; P:maintenance of gastrointestinal epithelium; ISS:BHF-UCL.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; IEA:InterPro.
DR   GO; GO:1901895; P:negative regulation of ATPase-coupled calcium transmembrane transporter activity; IDA:CACAO.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; ISS:BHF-UCL.
DR   GO; GO:0032717; P:negative regulation of interleukin-8 production; IDA:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050871; P:positive regulation of B cell activation; IDA:UniProtKB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IDA:UniProtKB.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:CACAO.
DR   GO; GO:0032725; P:positive regulation of granulocyte macrophage colony-stimulating factor production; IDA:CACAO.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:BHF-UCL.
DR   GO; GO:0002639; P:positive regulation of immunoglobulin production; IDA:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:UniProtKB.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:UniProtKB.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; ISS:BHF-UCL.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0032741; P:positive regulation of interleukin-18 production; ISS:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IC:BHF-UCL.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IDA:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IDA:BHF-UCL.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0034123; P:positive regulation of toll-like receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISS:BHF-UCL.
DR   GO; GO:0045577; P:regulation of B cell differentiation; IDA:UniProtKB.
DR   GO; GO:0034163; P:regulation of toll-like receptor 9 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0002237; P:response to molecule of bacterial origin; TAS:BHF-UCL.
DR   GO; GO:0034162; P:toll-like receptor 9 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0032640; P:tumor necrosis factor production; IDA:CACAO.
DR   Gene3D; 3.40.50.10140; -; 1.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR041283; LRR_12.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR027181; TLR9.
DR   InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR   PANTHER; PTHR47410:SF3; PTHR47410:SF3; 1.
DR   Pfam; PF18837; LRR_12; 1.
DR   Pfam; PF13516; LRR_6; 2.
DR   Pfam; PF13855; LRR_8; 7.
DR   Pfam; PF01582; TIR; 1.
DR   SMART; SM00369; LRR_TYP; 18.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52200; SSF52200; 1.
DR   PROSITE; PS51450; LRR; 17.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cytoplasmic vesicle; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Immunity;
KW   Inflammatory response; Innate immunity; Leucine-rich repeat; Lysosome;
KW   Membrane; Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..1032
FT                   /note="Toll-like receptor 9"
FT                   /id="PRO_0000034737"
FT   TOPO_DOM        26..818
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        819..839
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        840..1032
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          62..85
FT                   /note="LRR 1"
FT   REPEAT          87..110
FT                   /note="LRR 2"
FT   REPEAT          122..147
FT                   /note="LRR 3"
FT   REPEAT          150..166
FT                   /note="LRR 4"
FT   REPEAT          167..190
FT                   /note="LRR 5"
FT   REPEAT          198..221
FT                   /note="LRR 6"
FT   REPEAT          223..242
FT                   /note="LRR 7"
FT   REPEAT          243..268
FT                   /note="LRR 8"
FT   REPEAT          283..306
FT                   /note="LRR 9"
FT   REPEAT          308..332
FT                   /note="LRR 10"
FT   REPEAT          333..356
FT                   /note="LRR 11"
FT   REPEAT          363..386
FT                   /note="LRR 12"
FT   REPEAT          390..413
FT                   /note="LRR 13"
FT   REPEAT          415..440
FT                   /note="LRR 14"
FT   REPEAT          470..494
FT                   /note="LRR 15"
FT   REPEAT          496..519
FT                   /note="LRR 16"
FT   REPEAT          520..543
FT                   /note="LRR 17"
FT   REPEAT          545..572
FT                   /note="LRR 18"
FT   REPEAT          574..598
FT                   /note="LRR 19"
FT   REPEAT          600..622
FT                   /note="LRR 20"
FT   REPEAT          627..650
FT                   /note="LRR 21"
FT   REPEAT          652..675
FT                   /note="LRR 22"
FT   REPEAT          676..699
FT                   /note="LRR 23"
FT   REPEAT          701..723
FT                   /note="LRR 24"
FT   REPEAT          724..747
FT                   /note="LRR 25"
FT   REPEAT          749..772
FT                   /note="LRR 26"
FT   DOMAIN          868..1013
FT                   /note="TIR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT   REGION          47..51
FT                   /note="Interaction with CpG-DNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   REGION          72..77
FT                   /note="Interaction with CpG-DNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   REGION          95..109
FT                   /note="Interaction with CpG-DNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   REGION          179..181
FT                   /note="Interaction with CpG-DNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   BINDING         132
FT                   /note="CpG-DNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   BINDING         208
FT                   /note="CpG-DNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   CARBOHYD        64
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        129
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        200
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        210
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        242
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        300
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        340
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        469
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        474
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        513
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        567
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        694
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        731
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        35..45
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   DISULFID        98..110
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   DISULFID        178..184
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   DISULFID        255..268
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   DISULFID        258..265
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   DISULFID        470..500
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   DISULFID        764..790
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   DISULFID        766..809
FT                   /evidence="ECO:0000250|UniProtKB:Q2EEY0"
FT   VAR_SEQ         1..57
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11022119"
FT                   /id="VSP_006520"
FT   VAR_SEQ         1..16
FT                   /note="MGFCRSALHPLSLLVQ -> M (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11022120"
FT                   /id="VSP_006523"
FT   VAR_SEQ         1
FT                   /note="M -> MPMKWSGWRWSWGPATHTALPPPQ (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11022120"
FT                   /id="VSP_006521"
FT   VAR_SEQ         1
FT                   /note="M -> MLYSSCKSRLLDSVEQDFHLEIAKK (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11022120"
FT                   /id="VSP_006522"
FT   VARIANT         5
FT                   /note="R -> C (in dbSNP:rs5743842)"
FT                   /id="VAR_024668"
FT   VARIANT         79
FT                   /note="H -> Q (in dbSNP:rs5743843)"
FT                   /id="VAR_052364"
FT   VARIANT         863
FT                   /note="R -> Q (in dbSNP:rs5743845)"
FT                   /id="VAR_034555"
FT   VARIANT         882
FT                   /note="A -> T (in dbSNP:rs5743846)"
FT                   /id="VAR_052365"
FT   VARIANT         901
FT                   /note="R -> H (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs755472700)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036077"
FT   VARIANT         933
FT                   /note="T -> M (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs746622200)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036078"
FT   CONFLICT        200
FT                   /note="N -> S (in Ref. 7; AAQ89443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        330
FT                   /note="F -> L (in Ref. 7; AAQ89443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        530
FT                   /note="H -> R (in Ref. 2; AAF78037)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        688
FT                   /note="Q -> R (in Ref. 2; AAF78037)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1032 AA;  115860 MW;  71280AA9680EDCE2 CRC64;
     MGFCRSALHP LSLLVQAIML AMTLALGTLP AFLPCELQPH GLVNCNWLFL KSVPHFSMAA
     PRGNVTSLSL SSNRIHHLHD SDFAHLPSLR HLNLKWNCPP VGLSPMHFPC HMTIEPSTFL
     AVPTLEELNL SYNNIMTVPA LPKSLISLSL SHTNILMLDS ASLAGLHALR FLFMDGNCYY
     KNPCRQALEV APGALLGLGN LTHLSLKYNN LTVVPRNLPS SLEYLLLSYN RIVKLAPEDL
     ANLTALRVLD VGGNCRRCDH APNPCMECPR HFPQLHPDTF SHLSRLEGLV LKDSSLSWLN
     ASWFRGLGNL RVLDLSENFL YKCITKTKAF QGLTQLRKLN LSFNYQKRVS FAHLSLAPSF
     GSLVALKELD MHGIFFRSLD ETTLRPLARL PMLQTLRLQM NFINQAQLGI FRAFPGLRYV
     DLSDNRISGA SELTATMGEA DGGEKVWLQP GDLAPAPVDT PSSEDFRPNC STLNFTLDLS
     RNNLVTVQPE MFAQLSHLQC LRLSHNCISQ AVNGSQFLPL TGLQVLDLSH NKLDLYHEHS
     FTELPRLEAL DLSYNSQPFG MQGVGHNFSF VAHLRTLRHL SLAHNNIHSQ VSQQLCSTSL
     RALDFSGNAL GHMWAEGDLY LHFFQGLSGL IWLDLSQNRL HTLLPQTLRN LPKSLQVLRL
     RDNYLAFFKW WSLHFLPKLE VLDLAGNQLK ALTNGSLPAG TRLRRLDVSC NSISFVAPGF
     FSKAKELREL NLSANALKTV DHSWFGPLAS ALQILDVSAN PLHCACGAAF MDFLLEVQAA
     VPGLPSRVKC GSPGQLQGLS IFAQDLRLCL DEALSWDCFA LSLLAVALGL GVPMLHHLCG
     WDLWYCFHLC LAWLPWRGRQ SGRDEDALPY DAFVVFDKTQ SAVADWVYNE LRGQLEECRG
     RWALRLCLEE RDWLPGKTLF ENLWASVYGS RKTLFVLAHT DRVSGLLRAS FLLAQQRLLE
     DRKDVVVLVI LSPDGRRSRY VRLRQRLCRQ SVLLWPHQPS GQRSFWAQLG MALTRDNHHF
     YNRNFCQGPT AE
//
